scholarly journals Thyroid Functions Before and After Maintenance Hemodialysis in Patients with Chronic Renal Failure.

1988 ◽  
Vol 35 (6) ◽  
pp. 865-876 ◽  
Author(s):  
SHINICHI SAKURAI ◽  
YOSHIHITO HARA ◽  
SHIRO MIURA ◽  
MICHIYUKI URABE ◽  
KENICHI INOUE ◽  
...  
1994 ◽  
Vol 40 (8) ◽  
pp. 1544-1548 ◽  
Author(s):  
N C France ◽  
P T Holland ◽  
M R Wallace

Abstract We tested the possibility that the buffering agents in dialysis bath fluid might contribute to increased endogenous oxalate production in dialyzed patients. Using stable isotope dilution mass spectrometry, we obtained oxalate production rates and pool sizes directly for 10 patients in chronic renal failure, 5 of whom were undergoing continuous ambulatory peritoneal dialysis (lactate-buffered fluid). All peritoneal dialysis patients had either increased oxalate production rates or expanded oxalate pools when compared with undialyzed patients in renal failure. From a further four patients receiving maintenance hemodialysis we took blood samples immediately before and after three consecutive dialysis sessions in which the bath-fluid buffering agent (bicarbonate or acetate) was alternated; we analyzed these samples for oxalate and key precursors by capillary gas chromatography. Plasma glycine and serine concentrations remained within the physiological range. Glycolate and oxalate concentrations decreased, but the oxalate remained above normal after dialysis. All changes were independent of the bath-fluid buffering agent. We suggest that dialysis might stimulate the formation of oxalate by removing product inhibition of a late catabolic step.


2019 ◽  
Vol 25 (3) ◽  
pp. 230-254
Author(s):  
Farid Reza Ejlali ◽  
◽  
Mahmood Reza Khazaei ◽  
Zahra Mostafavian ◽  
Jalil Moshari ◽  
...  

Aims The aim of this study was to evaluate the effect of discontinuation of losartan in response to synthetic erythropoietin therapy on hemoglobin level in patients on maintenance hemodialysis. Methods & Materials This study was a pre-and post-interventional clinical trial. The population of the study was hemodialysis patients with chronic renal failure. In the beginning of the study, and three months after removal of losartan, the patients’ hemoglobin changes were compared. Findings Hemoglobin was significantly increased at the end of the study in all patients (from 10.90±1.66 at the beginning of the study to 11.37±1.42g/dl at the end of 3 months, P=0.046). No significant changes were seen in the hemoglobin level before and after intervention between patients according age, sex, and duration of the disease. Conclusion There was a significant increase in hemoglobin level at the end of study after losartan discontinuation. But this increase did not have a significant relationship with patient’s age, sex as well as the duration of the disease.


PEDIATRICS ◽  
1977 ◽  
Vol 60 (1) ◽  
pp. 46-50
Author(s):  
William A. Primack ◽  
Ira Greifer

A hemodialysis unit was established at a rural summer camp for children. Required medical treatment was planned so as to interfere as little as possible with normal camp programs. Campers who require dialysis were mixed fully into the population of normal campers. Twenty-two children participated during the first summer of operation. Our experience indicates that children on maintenance hemodialysis can be integrated with normal peers in a recreational program and can improve their self-image and self-confidence. The program also demonstrates that chronic pediatric hemodialysis can be safely performed in a rural satellite unit.


PEDIATRICS ◽  
1982 ◽  
Vol 70 (5) ◽  
pp. 742-750 ◽  
Author(s):  
Anthony C. Hsu ◽  
Sang Whay Kooh ◽  
Donald Fraser ◽  
William A. Cumming ◽  
Victor L. Fornasier

The incidence, age at onset, and progression of the biochemical, radiographic, and histologic characteristics of renal osteodystrophy were studied in 50 children in whom chronic renal failure had been recently diagnosed. During a ten-year observation period, 19 patients progressed to end-stage renal failure and radiographic signs of renal osteodystrophy developed in 15 of these (79%). Renal osteodystrophy developed in all nine patients whose chronic renal failure was diagnosed before 3 years of age and in six of the ten children with later onset of failure. The mean interval from diagnosis of renal failure to development of osteodystrophy was 1.4 years. Radiographically, growth zone lesions predominated in the younger children, whereas cortical erosions were more prevalent in the older children. Histologic examination, performed in 38 patients, showed both defective mineralization and excessive resorption and was a more sensitive diagnostic index than radiography. Noticeable deformities developed in one third of the patients with osteodystrophy, despite medical treatment including vitamin D2 therapy. Deformities were particularly frequent and Severe in patients whose renal failure developed in infancy. In all 13 patients whose growth patterns were studied before and after osteodystrophy developed, the onset of bone lesions was associated with a deterioration of growth, indicating that osteodystrophy plays a major role in causing the growth retardation commonly observed in children with chronic renal failure.


1995 ◽  
Vol 209 (1) ◽  
pp. 14-16 ◽  
Author(s):  
Dušica Pahor ◽  
Radovan Hojs ◽  
Bojan Gračner

1981 ◽  
Author(s):  
M Bern ◽  
J Green

Sulfinpyrazone can reduce the incidence of thrombosis of A-V shunts in chronic renal failure. The drug is also reported to prevent acute deaths from coronary artery disease. This study was to determine mechanisms for these protective effects.Patients on chronic hemodialysis served as the study models. Six patients on dialysis three times per week for 6 or more months received sulfinpyrazone 200 mgm t.i.d. p.o. for 14 days. Blood samples were obtained before dialysis was begun before and after the 14 days of drug therapy.Results are shown as mean ± standard error of mean.AT III levels rose significantly by functional and immune assays. Functional levels (by von Kaulla technique) rose 24.5 ± 3.1 sec. to 47.3 + 5.5 sec. (P>.005) Plasma protein AT III (by radial immunodiffusion) rose 31.2 ± 2.17 mg/dl to 37.9 ± 2.1 mgm/dl. (P>.01) Platelet factor 4 (by Abbot radioimmunology assay) fell from 46.4 + 13.6 ngm/ml to 9.5 ± 1.1 ngm/ml.(P>.005) The concentration of thrombin-anti-thrombin complex (by R. Rosenberg, Harvard Medical School, Boston) rose from 4.2 ± .09 to 8.4 ± 1.0 (P>.005)Thus it appears that sulfinpyrazone elevates antithrombin concentration and function while simultaneously suppressing platelet release. These two effects may or may not be mutually dependent. The clinical efficacy of sulfinpyrazone may relate in part to the elevation of antithrombin III, probably by inhibiting its consumption, while also inhibiting platelet function.


Sign in / Sign up

Export Citation Format

Share Document